【佳学基因检测】针对人类疾病中 FGF 信号网络的基因检测治疗

肿瘤基因检测哪家医院贼好解析

阅读肿瘤的正确化治疗及靶向药物选择发现《Trends Pharmacol Sci》在. 2016 Dec;37(12):1081-1096.发表了一篇题目为《针对人类疾病中 FGF 信号网络的治疗》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Masaru Katoh等完成。促进了肿瘤的正确治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及正确治疗临床研究内容关键词：

厄达非替尼,免疫检查点阻滞剂,英非拉替尼,小RNA,骨髓增生综合征,FGF

肿瘤靶向治疗基因检测临床应用结果

成纤维细胞生长因子 (FGF) 通过其受体 FGFR1、FGFR2、FGFR3 或 FGFR4 发出信号，调节细胞命运、血管生成、免疫和代谢。失调的 FGF 信号传导会导致人类疾病，例如乳腺癌、软骨发育不良、胃癌、肺癌和 X 连锁低磷性佝偻病。重组 FGF 是用于组织和/或伤口修复的前 FGF 信号疗法，而用于治疗心血管疾病、糖尿病和骨关节炎的 FGF 类似物和基因疗法正在开发中。 FGF 陷阱、抗 FGF/FGFR 单克隆抗体 (mAb) 和小分子 FGFR 抑制剂是正在开发的用于治疗癌症、软骨发育不良和佝偻病的抗 FGF 信号传导疗法。在这里，我将讨论靶向 FGFRs、ALK、EGFR 和 FLT3 的正确医疗的收益风险和成本效益问题。 FGFR 靶向治疗应针对癌症治疗进行优化，重点关注基因组检测和反复。厄达非替尼；免疫检查点阻滞剂；英非拉替尼；小RNA；骨髓增生综合征..基因解码基因检测的研究结果：超过 3700 名患者被纳入这项荟萃调查。 A3B 水平升高与 OS 低（合并 HR = 1.30；95% CI：1.09-1.55，P < 0.01）、DFS 差（合并 HR = 1.66；95% CI：1.17-2.35，P < 0.01）和RFS 差（HR = 1.51, 95% CI:1.11-2.04, P = 0.01）。亚组分析显示，高 A3B 表达与肺（HR = 1.85，95% CI：1.40-2.45）和乳腺癌（HR = 1.38，95% CI：1.00-1.89）的较差 OS 相关。 A3B的高表达与临床病理特征没有显着相关性。基因解码基因检测的研究结论：APOBEC3B过表达仅在某些癌症类型中与较差的OS、DFS和RFS有关，不能预测所有癌症的普遍作用。

肿瘤发生与反复转移国际数据库描述：

Fibroblast growth factor (FGF) signaling through its receptors, FGFR1, FGFR2, FGFR3, or FGFR4, regulates cell fate, angiogenesis, immunity, and metabolism. Dysregulated FGF signaling causes human diseases, such as breast cancer, chondrodysplasia, gastric cancer, lung cancer, and X-linked hypophosphatemic rickets. Recombinant FGFs are pro-FGF signaling therapeutics for tissue and/or wound repair, whereas FGF analogs and gene therapy are under development for the treatment of cardiovascular disease, diabetes, and osteoarthritis. FGF traps, anti-FGF/FGFR monoclonal antibodies (mAbs), and small-molecule FGFR inhibitors are anti-FGF signaling therapeutics under development for the treatment of cancer, chondrodysplasia, and rickets. Here, I discuss the benefit-risk and cost-effectiveness issues of precision medicine targeting FGFRs, ALK, EGFR, and FLT3. FGFR-targeted therapy should be optimized for cancer treatment, focusing on genomic tests and recurrence.Keywords: epithelial-to-mesenchymal transition; erdafitinib; immune-checkpoint blocker; infigratinib; miRNA; myeloproliferative syndrome..Results: Over 3700 patients were included in this meta-survey. Elevated levels of A3B were significantly related to low OS (pooled HR = 1.30; 95% CI:1.09-1.55, P < 0.01), poor DFS (pooled HR = 1.66; 95% CI:1.17-2.35, P < 0.01) and poor RFS (HR = 1.51, 95% CI:1.11-2.04, P = 0.01). Subgroup analysis revealed that high A3B expression was associated with poor OS in lung (HR = 1.85, 95% CI: 1.40-2.45), and breast cancers (HR = 1.38, 95% CI: 1.00-1.89). High expression of A3B did not display any significant association with clinicopathologic features.Conclusion: APOBEC3B overexpression is related to poor OS, DFS and RFS only in some cancer types and no generalized role could be predicted for all cancers.